105 related articles for article (PubMed ID: 22587883)
21. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
[TBL] [Abstract][Full Text] [Related]
22. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1.
Picon A; Gold LI; Wang J; Cohen A; Friedman E
Cancer Epidemiol Biomarkers Prev; 1998 Jun; 7(6):497-504. PubMed ID: 9641494
[TBL] [Abstract][Full Text] [Related]
23. Role of transforming growth factor beta in cancer.
Pasche B
J Cell Physiol; 2001 Feb; 186(2):153-68. PubMed ID: 11169452
[TBL] [Abstract][Full Text] [Related]
24. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
Deckers M; van Dinther M; Buijs J; Que I; Löwik C; van der Pluijm G; ten Dijke P
Cancer Res; 2006 Feb; 66(4):2202-9. PubMed ID: 16489022
[TBL] [Abstract][Full Text] [Related]
25. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.
Wiercinska E; Naber HP; Pardali E; van der Pluijm G; van Dam H; ten Dijke P
Breast Cancer Res Treat; 2011 Aug; 128(3):657-66. PubMed ID: 20821046
[TBL] [Abstract][Full Text] [Related]
26. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling.
Labelle M; Schnittler HJ; Aust DE; Friedrich K; Baretton G; Vestweber D; Breier G
Cancer Res; 2008 Mar; 68(5):1388-97. PubMed ID: 18316602
[TBL] [Abstract][Full Text] [Related]
28. Targeting TGF-β Signaling in Cancer.
Colak S; Ten Dijke P
Trends Cancer; 2017 Jan; 3(1):56-71. PubMed ID: 28718426
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta inhibitors for the treatment of cancer.
Lahn M; Kloeker S; Berry BS
Expert Opin Investig Drugs; 2005 Jun; 14(6):629-43. PubMed ID: 16004592
[TBL] [Abstract][Full Text] [Related]
30. Complexities of TGF-β targeted cancer therapy.
Connolly EC; Freimuth J; Akhurst RJ
Int J Biol Sci; 2012; 8(7):964-78. PubMed ID: 22811618
[TBL] [Abstract][Full Text] [Related]
31. Targeting aberrant TGF-beta signaling in pre-clinical models of cancer.
Mourskaia AA; Northey JJ; Siegel PM
Anticancer Agents Med Chem; 2007 Sep; 7(5):504-14. PubMed ID: 17896911
[TBL] [Abstract][Full Text] [Related]
32. The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.
Grusch M; Petz M; Metzner T; Oztürk D; Schneller D; Mikulits W
Curr Cancer Drug Targets; 2010 Dec; 10(8):849-57. PubMed ID: 20718708
[TBL] [Abstract][Full Text] [Related]
33. Targeting TGF-β signaling in cancer.
Katz LH; Li Y; Chen JS; Muñoz NM; Majumdar A; Chen J; Mishra L
Expert Opin Ther Targets; 2013 Jul; 17(7):743-60. PubMed ID: 23651053
[TBL] [Abstract][Full Text] [Related]
34. Natural products and transforming growth factor-beta (TGF-β) signaling in cancer development and progression.
Lee C; Zhang Q; Kozlowski J; Brendler C; B Soares M; Dash A; McClelland M; Mercola D
Curr Cancer Drug Targets; 2013 Jun; 13(5):500-5. PubMed ID: 23597196
[TBL] [Abstract][Full Text] [Related]
35. TGF-β in radiotherapy: Mechanisms of tumor resistance and normal tissues injury.
Farhood B; Khodamoradi E; Hoseini-Ghahfarokhi M; Motevaseli E; Mirtavoos-Mahyari H; Eleojo Musa A; Najafi M
Pharmacol Res; 2020 May; 155():104745. PubMed ID: 32145401
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor-β signaling and cancer: the 28th Sapporo Cancer Seminar, 25-27 June 2008.
Miyazono K
Cancer Sci; 2009 Feb; 100(2):363-5. PubMed ID: 19068084
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of therapies targeting TGF-β in solid tumors: a systematic review and meta-analysis of clinical trials.
Rahavi H; Alizadeh-Navaei R; Tehrani M
Immunotherapy; 2023 Mar; 15(4):283-292. PubMed ID: 36789642
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Transforming Growth Factor-β Signaling in Cancer Therapy.
Sheen YY; Kim MJ; Park SA; Park SY; Nam JS
Biomol Ther (Seoul); 2013 Sep; 21(5):323-31. PubMed ID: 24244818
[TBL] [Abstract][Full Text] [Related]
39. Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin.
Tewari D; Priya A; Bishayee A; Bishayee A
Clin Transl Med; 2022 Apr; 12(4):e795. PubMed ID: 35384373
[TBL] [Abstract][Full Text] [Related]
40. TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression.
Lamora A; Talbot J; Mullard M; Brounais-Le Royer B; Redini F; Verrecchia F
J Clin Med; 2016 Nov; 5(11):. PubMed ID: 27827889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
